NPS Pharmaceuticals gets positive results with drug for endocrine disorder

NPS Pharmaceuticals (NASDAQ: NPSP), a Bedminster, New Jersey-based orphan drug developer, saw  positive results using a hormone replacement therapy drug in a phase 3 clinical trial to treat hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, the principal regulator of calcium and phosphorus, and for which […]